Trump Slashes Obesity Drug Prices with Lilly, Novo Nordisk Deals

President Trump announced deals with Eli Lilly and Novo Nordisk to slash GLP-1 obesity drug prices for Medicare/Medicaid and launch TrumpRx.gov. Medicare coverage for these costly treatments begins mid-2026.